文献速递乳腺癌

多灶同侧乳腺癌保乳治疗后的局部复发:ACOSOG Z11102(Alliance)研究结果

Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance).
PubMed 文献 · J Clin Oncol · 2023-03-28

ACOSOG Z11102是一项II期单臂前瞻性试验,评估多灶同侧乳腺癌患者接受保乳治疗的肿瘤学安全性。204例可评估患者接受肿块切除阴性切缘后全乳放疗并对所有瘤床加量,中位随访66.4个月,5年局部复发累积发生率为3.1%(95%CI 1.3-6.4),低于预设的8%临床可接受率。探索性分析显示术前未行乳腺MRI者5年局部复发率为22.6%,而行MRI者为1.7%(P=.002)。

要点

  • 多灶同侧乳腺癌保乳术后5年局部复发累积发生率为3.1%(95%CI 1.3-6.4),低于预设8%的可接受阈值。
  • 术前未行乳腺MRI者5年局部复发率为22.6%,术前行MRI者为1.7%(P=.002),为探索性分析结果。
  • 患者年龄、术前活检证实病灶数、雌激素受体状态、人表皮生长因子受体2状态及病理T、N分期与局部复发风险无关联。

核心结论

  • Z11102临床试验表明,对于多灶同侧乳腺癌,保乳手术联合包含瘤床加量的辅助放疗可获得可接受的低5年局部复发率。
  • 该证据支持将保乳治疗作为有2至3个同侧病灶女性的合理手术选择,尤其是在术前经乳腺MRI评估的患者中。

研究设计与样本

  • ACOSOG Z11102(Alliance)是一项II期、单臂、前瞻性试验,旨在评估多灶同侧乳腺癌患者接受保乳治疗的肿瘤学结局。
  • 入组标准为年龄40岁及以上、有2至3个活检证实的cN0-1乳腺癌病灶的女性。
  • 患者接受肿块切除术并达到阴性切缘,随后行全乳放疗并对所有肿块切除瘤床加量。
  • 主要终点为5年局部复发累积发生率,预设临床可接受率为<8%。
  • 2012年11月至2016年8月共入组270例女性,其中204例符合条件并接受方案指导的保乳治疗。

主要发现

  • 204例可评估患者中,6例发生局部复发,估计5年局部复发累积发生率为3.1%(95%CI 1.3-6.4)。
  • 患者年龄、术前活检证实乳腺癌的病灶数、雌激素受体状态、人表皮生长因子受体2状态及病理T和N分期与局部复发风险无关联。
  • 探索性分析显示,术前未行乳腺MRI的患者(n=15)5年局部复发率为22.6%,而行术前乳腺MRI的患者(n=189)为1.7%(P=.002)。

关键数值与推荐

  • 主要终点5年局部复发累积发生率为3.1%(95%CI 1.3-6.4),低于预设的临床可接受率<8%。
  • 术前未行乳腺MRI者(n=15)5年局部复发率为22.6%,术前行乳腺MRI者(n=189)为1.7%(P=.002)。

临床怎么用

  • 作者结论认为,保乳手术联合包含瘤床加量的辅助放疗可使多灶同侧乳腺癌获得可接受的低5年局部复发率。
  • 作者结论认为,该证据支持保乳治疗作为有2至3个同侧病灶女性的合理手术选择,尤其在术前经乳腺MRI评估的患者中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Breast-conserving therapy (BCT) is the preferred treatment for unifocal breast cancer (BC). The oncologic safety of BCT for multiple ipsilateral breast cancer (MIBC) has not been demonstrated in a prospective study. ACOSOG Z11102 (Alliance) is a phase II, single-arm, prospective trial designed to evaluate oncologic outcomes in patients undergoing BCT for MIBC. PATIENTS AND METHODS: Women age 40 years and older with two to three foci of biopsy-proven cN0-1 BC were eligible. Patients underwent lumpectomies with negative margins followed by whole breast radiation with boost to all lumpectomy beds. The primary end point was cumulative incidence of local recurrence (LR) at 5 years with an a priori rate of clinical acceptability of <8%. RESULTS: Among 270 women enrolled between November 2012 and August 2016, there were 204 eligible patients who underwent protocol-directed BCT. The median age was 61 years (range, 40-87 years). At a median follow-up of 66.4 months (range, 1.3-90.6 months), six patients developed LR for an estimated 5-year cumulative incidence of LR of 3.1% (95% CI, 1.3 to 6.4). Patient age, number of sites of preoperative biopsy-proven BC, estrogen receptor status and human epidermal growth factor receptor 2 status, and pathologic T and N categories were not associated with LR risk. Exploratory analysis showed that the 5-year LR rate in patients without preoperative magnetic resonance imaging (MRI; n = 15) was 22.6% compared with 1.7% in patients with a preoperative MRI (n = 189; P = .002). CONCLUSION: The Z11102 clinical trial demonstrates that breast-conserving surgery with adjuvant radiation that includes lumpectomy site boosts yields an acceptably low 5-year LR rate for MIBC. This evidence supports BCT as a reasonable surgical option for women with two to three ipsilateral foci, particularly among patients with disease evaluated with preoperative breast MRI.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Boughey JC, Rosenkranz KM, Ballman KV, et al. Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance). J Clin Oncol. 2023. PMID: 36977292. doi:10.1200/JCO.22.02553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。